| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/30/2011 | EP2301626A2 Antibiotic for use in local infection |
| 03/30/2011 | EP2301625A2 Compositions and methods for treating cognitive disorders |
| 03/30/2011 | EP2301593A1 Thermoplastic paste for repairing living tissues |
| 03/30/2011 | EP2301573A1 Anti-cancer and anti-infectious disease compositions and methods for using same |
| 03/30/2011 | EP2301567A1 Selective immune down regulation (SIDR) for transplantation |
| 03/30/2011 | EP2301566A1 DNA vaccines encoding heat shock proteins |
| 03/30/2011 | EP2301565A1 Use of proteasome inhibitors for the treatment of viral infections |
| 03/30/2011 | EP2301562A1 Irrigation solution and method for inhibition of pain, inflammation and spasm |
| 03/30/2011 | EP2301560A1 Pharmaceutical agent for promoting the functional regeneration of damaged tissue |
| 03/30/2011 | EP2301556A1 Co-Administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer |
| 03/30/2011 | EP2301555A1 Cream-like o/w type emulsified composition and method for producing same |
| 03/30/2011 | EP2301554A1 Composition for the treatment of osteoarthritis |
| 03/30/2011 | EP2301553A1 Polynucleotide therapy |
| 03/30/2011 | EP2301552A1 Polynucleotide therapy |
| 03/30/2011 | EP2301551A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 03/30/2011 | EP2301550A1 Tetracycline compounds having target therapeutic activities |
| 03/30/2011 | EP2301549A1 Remedies for diseases to be applied to eye |
| 03/30/2011 | EP2301548A1 Stannsoporfin compositions and administration |
| 03/30/2011 | EP2301547A1 Use of activators of soluble guanylate cyclase for improving wound healing |
| 03/30/2011 | EP2301546A1 Treatment of metastasized tumors |
| 03/30/2011 | EP2301545A1 Thioxanthene derivatives for use in the treatment of infectious diseases |
| 03/30/2011 | EP2301544A1 Quinoline derivatives as intermediates to mycobacterial inhibitors |
| 03/30/2011 | EP2301543A1 A pharmaceutical composition for treating diabetes |
| 03/30/2011 | EP2301542A1 Controlled-release compositions containing opioid agonist and antagonist |
| 03/30/2011 | EP2301541A1 Antibiotic compositions for treatment of the eye, ear and nose |
| 03/30/2011 | EP2301540A1 A therapeutic agent for impaired gastric accomodation |
| 03/30/2011 | EP2301539A1 PPAR gamma agonists for treating illnesses with pathophysiological participation of TH17 lymphocytes |
| 03/30/2011 | EP2301538A1 Compounds for nonsense suppression, and methods for their use |
| 03/30/2011 | EP2301537A1 Zonisamide for the treatment of obesity |
| 03/30/2011 | EP2301536A1 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 03/30/2011 | EP2301535A1 Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| 03/30/2011 | EP2301534A1 Amino-methyl substituted tetracycline compounds |
| 03/30/2011 | EP2301533A1 Wortmannin Analogs and Method of Using Same |
| 03/30/2011 | EP2301532A1 Use of statins as anticonvulsants, antiepileptics and neuroprotectors |
| 03/30/2011 | EP2301531A2 Combinations and modes of administration of therapeutic agents and combination therapy |
| 03/30/2011 | EP2301530A1 Use of a fatty acid composition comprising EPA and DHA for reducing body weight |
| 03/30/2011 | EP2301529A1 Hydroxymethylbutyrate compositions and uses thereof |
| 03/30/2011 | EP2301528A1 Use of FTS for treating malignant disorders |
| 03/30/2011 | EP2301527A1 Association of agomelatine with a mood stabilizer, and pharmaceutical compositions comprising them |
| 03/30/2011 | EP2301526A2 Morphine controlled release system |
| 03/30/2011 | EP2301525A1 Topical ibuprofen formulation |
| 03/30/2011 | EP2301524A1 Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections |
| 03/30/2011 | EP2301494A1 Sustained analgesia achieved with buprenorphine |
| 03/30/2011 | EP2301493A1 Sustained analgesia achieved with buprenorphine |
| 03/30/2011 | EP2301368A1 Composition for prevention against spoilage by microorganisms and uses and products related thereto |
| 03/30/2011 | EP2301349A2 Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
| 03/30/2011 | EP2300624A1 Biomarkers for painful intervertebral discs and methods of use thereof |
| 03/30/2011 | EP2300514A1 A method of synthesizing a substantially monodispersed mixture of oligomers |
| 03/30/2011 | EP2300496A1 Methods of treating atherosclerosis |
| 03/30/2011 | EP2300490A1 Hepatitis c virus inhibitors |
| 03/30/2011 | EP2300485A1 Pyrrolo ý2, 3-c¨pyridine derivatives as p38 kinase inhibiting agents |
| 03/30/2011 | EP2300484A1 Novel class of spiro piperidines for the treatment of neurodegenerative diseases |
| 03/30/2011 | EP2300483A1 Triazine compounds as p13 kinase and mtor inhibitors |
| 03/30/2011 | EP2300482A1 Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof |
| 03/30/2011 | EP2300481A2 Novel substituted azabenzoxazoles |
| 03/30/2011 | EP2300479A1 Nalmefene hydrochloride dihydrate |
| 03/30/2011 | EP2300478A1 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators |
| 03/30/2011 | EP2300477A1 Tricyclic nitrogen containing compounds and their use as antibacterials |
| 03/30/2011 | EP2300476A1 Tricyclic nitrogen containing compounds and their use as antibacterials |
| 03/30/2011 | EP2300475A1 Diazacarbazoles and methods of use |
| 03/30/2011 | EP2300473A2 Fumarate salt of 4-bromophenyl 1,4-diazabicycloý3.2.2¨nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof |
| 03/30/2011 | EP2300472A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 03/30/2011 | EP2300469A2 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| 03/30/2011 | EP2300468A1 Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido ý 3, 2, 1-i j¨quinoline compounds |
| 03/30/2011 | EP2300466A1 Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| 03/30/2011 | EP2300465A1 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases |
| 03/30/2011 | EP2300464A1 Quinuclidine derivatives as muscarinic m3 receptor antagonists |
| 03/30/2011 | EP2300463A1 Heterocyclic urea derivatives for the treatment of bacterial infections |
| 03/30/2011 | EP2300462A1 Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
| 03/30/2011 | EP2300461A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 03/30/2011 | EP2300460A1 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 03/30/2011 | EP2300459A1 Novel phenylpyrazinones as kinase inhibitors |
| 03/30/2011 | EP2300457A1 Substituted pyrroles and methods of use |
| 03/30/2011 | EP2300456A1 Bicyclic compounds having activity at the cxcr4 receptor |
| 03/30/2011 | EP2300455A2 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl) - imidazo [1, 2-b] [1, 2, 4] triazin-2-yl] benzamide and processes related to preparing the same |
| 03/30/2011 | EP2300453A1 3, 4 - substituted piperidine derivatives as renin inhibitors |
| 03/30/2011 | EP2300452A1 5-ý5-ý2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino¨-4-(4-fluoro-2-methylphenyl)¨-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists |
| 03/30/2011 | EP2300443A1 Triazole derivatives useful for the treatment of diseases |
| 03/30/2011 | EP2300442A2 Compounds and methods for modulating g protein-coupled receptors |
| 03/30/2011 | EP2300441A1 Crystalline salt forms of antifolate compounds and methods of manufacturing thereof |
| 03/30/2011 | EP2300440A1 3,4-dihydropyrimidine trpa1 antagonists |
| 03/30/2011 | EP2300439A1 Therapeutic substituted hydantoins, and related compounds |
| 03/30/2011 | EP2300438A1 Imidazole derivatives useful as inhibitors of faah |
| 03/30/2011 | EP2300437A1 Benzpyrazol derivatives as inhibitors of pi3 kinases |
| 03/30/2011 | EP2300436A1 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
| 03/30/2011 | EP2300435A2 Heterocyclic compounds as factor ixa inhibitors |
| 03/30/2011 | EP2300434A1 Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors |
| 03/30/2011 | EP2300433A1 Hiv integrase inhibitors from pyridoxine |
| 03/30/2011 | EP2300432A1 Piperazine derivatives used as cav2.2 calcium channel modulators |
| 03/30/2011 | EP2300430A1 Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
| 03/30/2011 | EP2300428A1 Aminopyridine derivatives |
| 03/30/2011 | EP2300427A1 Urea compounds as gamma secretase modulators |
| 03/30/2011 | EP2300426A1 Compounds comprising a cyclobutoxy group |
| 03/30/2011 | EP2300425A2 Cycloalkaneýb¨indole angtagonists of prostaglandin d2 receptors |
| 03/30/2011 | EP2300424A2 Use of indole derivatives as nurr-1 activators for treating parkinson s disease |
| 03/30/2011 | EP2300423A1 Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof |
| 03/30/2011 | EP2300422A1 Azetidines and cyclobutanes as histamine h3 receptor antagonists |
| 03/30/2011 | EP2300412A1 Prostaglandin produgs as hypotensive agents |
| 03/30/2011 | EP2300102A2 Long term disease modification using immunostimulatory oligonucleotides |
| 03/30/2011 | EP2300056A2 Compliant composites for application of drug-eluting coatings to tissue surfaces |